Identifying vulnerabilities and therapeutic targets in Glioma Stem Cells View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2015-2018

FUNDING AMOUNT

602640 USD

ABSTRACT

? DESCRIPTION (provided by applicant): The objective of this application is to develop the career of Dr. Christian Badr to facilitate the transition to a stable independent phase and attain his ultimate goal to become an independent scientist and establish his own research program. The career development plan created by the candidate will contribute substantially to his scientific development and further his training in proteomics, RNAi and cancer stem cells biology. The proposed opportunity in the K22 will provide the PI protected time while starting his independent Faculty position and direct him towards a successful career in developing therapeutics for brain tumors. The proposed research will also serve as the foundation for an R01 proposal prior to the end of the second year of this award. Glioma stem cells (GSC) represent a subset population within malignant gliomas, and are highly tumorigenic, intrinsically resistant to current therapies, and capable of self-renewal and differentiation into mature glioma cells (GCs). There are two major subtypes of GSCs: Proneural (PN) and Mesenchymal (MES), the latter being more aggressive and more resistant to conventional treatment. We have identified a subpopulation of GSCs, termed floating cells (FC) that could be isolated from in vitro-cultured glioma cells. These cells possess a stem-like signature with prominent mesenchymal features. They tend to be more aggressive when implanted into the brain of nude mice as compared to their parental GSCs line and have a superior resistance to radiation and therapy. Due to such properties, FC represents an ideal model to identify and test new GBM therapeutics. In Aim 1 of this proposal we will use quantitative mass spectrometry to perform a proteomic analysis on different models of PN and MES GSCs including the FC population. This work will provide a deeper characterization of the FCs and identify differentially expressed proteins/pathways in PN and MES GSCs, which could be exploited to develop new therapeutics. In Aim 2, we will use imaging-based reporters and perform an RNAi screen to identify GSCs modulators which either push GSCs to a more differentiated state, making them susceptible to conventional therapy, or simply kill these cells. Finally we will test a novel gene delivery approach based on extracellular vesicles packaged in adeno-associated virus vectors (vAAV) to deliver our therapeutic RNAi to brain tumors in mice. This work can add valuable information for understanding the biology of this elusive tumor population and plasticity between GSCs subtypes. It also has the potential to identify new vulnerabilities and therapeutic avenues for PN and MES gliomas. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=9314386

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "602640"
    }, 
    "description": "? DESCRIPTION (provided by applicant): The objective of this application is to develop the career of Dr. Christian Badr to facilitate the transition to a stable independent phase and attain his ultimate goal to become an independent scientist and establish his own research program. The career development plan created by the candidate will contribute substantially to his scientific development and further his training in proteomics, RNAi and cancer stem cells biology. The proposed opportunity in the K22 will provide the PI protected time while starting his independent Faculty position and direct him towards a successful career in developing therapeutics for brain tumors. The proposed research will also serve as the foundation for an R01 proposal prior to the end of the second year of this award. Glioma stem cells (GSC) represent a subset population within malignant gliomas, and are highly tumorigenic, intrinsically resistant to current therapies, and capable of self-renewal and differentiation into mature glioma cells (GCs). There are two major subtypes of GSCs: Proneural (PN) and Mesenchymal (MES), the latter being more aggressive and more resistant to conventional treatment. We have identified a subpopulation of GSCs, termed floating cells (FC) that could be isolated from in vitro-cultured glioma cells. These cells possess a stem-like signature with prominent mesenchymal features. They tend to be more aggressive when implanted into the brain of nude mice as compared to their parental GSCs line and have a superior resistance to radiation and therapy. Due to such properties, FC represents an ideal model to identify and test new GBM therapeutics. In Aim 1 of this proposal we will use quantitative mass spectrometry to perform a proteomic analysis on different models of PN and MES GSCs including the FC population. This work will provide a deeper characterization of the FCs and identify differentially expressed proteins/pathways in PN and MES GSCs, which could be exploited to develop new therapeutics. In Aim 2, we will use imaging-based reporters and perform an RNAi screen to identify GSCs modulators which either push GSCs to a more differentiated state, making them susceptible to conventional therapy, or simply kill these cells. Finally we will test a novel gene delivery approach based on extracellular vesicles packaged in adeno-associated virus vectors (vAAV) to deliver our therapeutic RNAi to brain tumors in mice. This work can add valuable information for understanding the biology of this elusive tumor population and plasticity between GSCs subtypes. It also has the potential to identify new vulnerabilities and therapeutic avenues for PN and MES gliomas.", 
    "endDate": "2018-09-29T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.48336.3a", 
      "type": "Organization"
    }, 
    "id": "sg:grant.4455923", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "4455923"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "K22CA197053"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "plasticity", 
      "glioma stem cells", 
      "Fc", 
      "opportunity", 
      "conventional therapy", 
      "vulnerability", 
      "mice", 
      "FCS", 
      "FC population", 
      "radiation", 
      "differentiated state", 
      "RNAi screen", 
      "research", 
      "current therapies", 
      "valuable information", 
      "new therapeutics", 
      "brain", 
      "brain tumors", 
      "GSCs subtypes", 
      "end", 
      "Aim 2", 
      "Glioma Stem Cells", 
      "GCs", 
      "OBJECTIVE", 
      "proneural", 
      "work", 
      "therapeutic target", 
      "application", 
      "candidates", 
      "elusive tumor population", 
      "proteomics", 
      "transition", 
      "award", 
      "malignant gliomas", 
      "therapeutic RNAi", 
      "independent scientists", 
      "different models", 
      "GSCs modulators", 
      "cancer stem cell biology", 
      "successful career", 
      "new vulnerabilities", 
      "superior resistance", 
      "proposal", 
      "deep characterization", 
      "prominent mesenchymal features", 
      "extracellular vesicles", 
      "proteins/pathways", 
      "time", 
      "therapeutic avenues", 
      "MES GSCs", 
      "Pi", 
      "Aim 1", 
      "MES gliomas", 
      "stable independent phase", 
      "K22", 
      "differentiation", 
      "foundation", 
      "description", 
      "applicants", 
      "major subtypes", 
      "RNAi", 
      "subset population", 
      "stem-like signature", 
      "biology", 
      "training", 
      "quantitative mass spectrometry", 
      "independent Faculty position", 
      "reporter", 
      "therapy", 
      "cells", 
      "proteomic analysis", 
      "career development plans", 
      "subpopulations", 
      "adeno", 
      "therapeutics", 
      "vAAV", 
      "virus vector", 
      "Dr. Christian Badr", 
      "ideal model", 
      "R01 proposal", 
      "parental GSCs line", 
      "own research program", 
      "conventional treatment", 
      "such properties", 
      "ultimate goal", 
      "second year", 
      "scientific development", 
      "new GBM therapeutics", 
      "career", 
      "self-renewal", 
      "novel gene delivery approach", 
      "mesenchymal", 
      "vitro-cultured glioma cells", 
      "nude mice", 
      "imaging"
    ], 
    "name": "Identifying vulnerabilities and therapeutic targets in Glioma Stem Cells", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.32224.35", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.32224.35", 
          "name": "MASSACHUSETTS GENERAL HOSPITAL", 
          "type": "Organization"
        }, 
        "familyName": "BADR", 
        "givenName": "CHRISTIAN ELIAS", 
        "id": "sg:person.0642200116.13", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.0642200116.13", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.4455923"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T12:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_3.xml.gz", 
    "startDate": "2015-09-30T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=9314386"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.4455923'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.4455923'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.4455923'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.4455923'


 

This table displays all metadata directly associated to this object as RDF triples.

139 TRIPLES      19 PREDICATES      117 URIs      109 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.4455923 schema:about anzsrc-for:2211
2 schema:amount N514ae57350a7433ba1d45d1ed5929b2d
3 schema:description ? DESCRIPTION (provided by applicant): The objective of this application is to develop the career of Dr. Christian Badr to facilitate the transition to a stable independent phase and attain his ultimate goal to become an independent scientist and establish his own research program. The career development plan created by the candidate will contribute substantially to his scientific development and further his training in proteomics, RNAi and cancer stem cells biology. The proposed opportunity in the K22 will provide the PI protected time while starting his independent Faculty position and direct him towards a successful career in developing therapeutics for brain tumors. The proposed research will also serve as the foundation for an R01 proposal prior to the end of the second year of this award. Glioma stem cells (GSC) represent a subset population within malignant gliomas, and are highly tumorigenic, intrinsically resistant to current therapies, and capable of self-renewal and differentiation into mature glioma cells (GCs). There are two major subtypes of GSCs: Proneural (PN) and Mesenchymal (MES), the latter being more aggressive and more resistant to conventional treatment. We have identified a subpopulation of GSCs, termed floating cells (FC) that could be isolated from in vitro-cultured glioma cells. These cells possess a stem-like signature with prominent mesenchymal features. They tend to be more aggressive when implanted into the brain of nude mice as compared to their parental GSCs line and have a superior resistance to radiation and therapy. Due to such properties, FC represents an ideal model to identify and test new GBM therapeutics. In Aim 1 of this proposal we will use quantitative mass spectrometry to perform a proteomic analysis on different models of PN and MES GSCs including the FC population. This work will provide a deeper characterization of the FCs and identify differentially expressed proteins/pathways in PN and MES GSCs, which could be exploited to develop new therapeutics. In Aim 2, we will use imaging-based reporters and perform an RNAi screen to identify GSCs modulators which either push GSCs to a more differentiated state, making them susceptible to conventional therapy, or simply kill these cells. Finally we will test a novel gene delivery approach based on extracellular vesicles packaged in adeno-associated virus vectors (vAAV) to deliver our therapeutic RNAi to brain tumors in mice. This work can add valuable information for understanding the biology of this elusive tumor population and plasticity between GSCs subtypes. It also has the potential to identify new vulnerabilities and therapeutic avenues for PN and MES gliomas.
4 schema:endDate 2018-09-29T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.48336.3a
6 schema:identifier N013c35998902435486cfa480346c5a50
7 N27639f75024a40bcbb4fc622119eea21
8 schema:inLanguage en
9 schema:keywords Aim 1
10 Aim 2
11 Dr. Christian Badr
12 FC population
13 FCS
14 Fc
15 GCs
16 GSCs modulators
17 GSCs subtypes
18 Glioma Stem Cells
19 K22
20 MES GSCs
21 MES gliomas
22 OBJECTIVE
23 Pi
24 R01 proposal
25 RNAi
26 RNAi screen
27 adeno
28 applicants
29 application
30 award
31 biology
32 brain
33 brain tumors
34 cancer stem cell biology
35 candidates
36 career
37 career development plans
38 cells
39 conventional therapy
40 conventional treatment
41 current therapies
42 deep characterization
43 description
44 different models
45 differentiated state
46 differentiation
47 elusive tumor population
48 end
49 extracellular vesicles
50 foundation
51 glioma stem cells
52 ideal model
53 imaging
54 independent Faculty position
55 independent scientists
56 major subtypes
57 malignant gliomas
58 mesenchymal
59 mice
60 new GBM therapeutics
61 new therapeutics
62 new vulnerabilities
63 novel gene delivery approach
64 nude mice
65 opportunity
66 own research program
67 parental GSCs line
68 plasticity
69 prominent mesenchymal features
70 proneural
71 proposal
72 proteins/pathways
73 proteomic analysis
74 proteomics
75 quantitative mass spectrometry
76 radiation
77 reporter
78 research
79 scientific development
80 second year
81 self-renewal
82 stable independent phase
83 stem-like signature
84 subpopulations
85 subset population
86 successful career
87 such properties
88 superior resistance
89 therapeutic RNAi
90 therapeutic avenues
91 therapeutic target
92 therapeutics
93 therapy
94 time
95 training
96 transition
97 ultimate goal
98 vAAV
99 valuable information
100 virus vector
101 vitro-cultured glioma cells
102 vulnerability
103 work
104 schema:name Identifying vulnerabilities and therapeutic targets in Glioma Stem Cells
105 schema:recipient Neda8292523a44668b7e031270d8c0c0d
106 sg:person.0642200116.13
107 https://www.grid.ac/institutes/grid.32224.35
108 schema:sameAs https://app.dimensions.ai/details/grant/grant.4455923
109 schema:sdDatePublished 2019-03-07T12:10
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher Nfce790e3c1ef404a95f459b1b01ba2f9
112 schema:startDate 2015-09-30T00:00:00Z
113 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=9314386
114 sgo:license sg:explorer/license/
115 sgo:sdDataset grants
116 rdf:type schema:MonetaryGrant
117 N013c35998902435486cfa480346c5a50 schema:name dimensions_id
118 schema:value 4455923
119 rdf:type schema:PropertyValue
120 N27639f75024a40bcbb4fc622119eea21 schema:name nih_id
121 schema:value K22CA197053
122 rdf:type schema:PropertyValue
123 N514ae57350a7433ba1d45d1ed5929b2d schema:currency USD
124 schema:value 602640
125 rdf:type schema:MonetaryAmount
126 Neda8292523a44668b7e031270d8c0c0d schema:member sg:person.0642200116.13
127 schema:roleName PI
128 rdf:type schema:Role
129 Nfce790e3c1ef404a95f459b1b01ba2f9 schema:name Springer Nature - SN SciGraph project
130 rdf:type schema:Organization
131 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
132 rdf:type schema:DefinedTerm
133 sg:person.0642200116.13 schema:affiliation https://www.grid.ac/institutes/grid.32224.35
134 schema:familyName BADR
135 schema:givenName CHRISTIAN ELIAS
136 rdf:type schema:Person
137 https://www.grid.ac/institutes/grid.32224.35 schema:name MASSACHUSETTS GENERAL HOSPITAL
138 rdf:type schema:Organization
139 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
 




Preview window. Press ESC to close (or click here)


...